Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HERE IT IS, The TOP Earnings, 5 year and 6 month charts combined..... These are the best bets on the markets !!!
This list is screened for recent pps performance using the 6 month charts. The stocks are gathered from growing Year to Year and Quarter To Quarter Earnings AND EPS growth stocks. The stocks were then screened using a 5 year chart screening method of looking for steady pps growth and a great chart pattern of rising close to a 45 degree angle on a constant basis. The first step in screening these included filtering through EVERY stock in a list of 15,000 or so Nasdaq, NYSE, and Amex stocks by checking the financials of EACH for EPS and Revenue. First negative EPS was screened, than a look Year to Year and Quarter to Quarter for EPS and Earnings screened. Once a final list of top earnings, eps and 5 year chart performance stocks were gathered they were AGAIN screened for a MINIMUM of 200% 6 month chart results. This will assure the best potential in achieving gains on a RECENT month to month basis in a consistent manner.
Abondanza:
aai,actu,adam,airm,akam,amd,ati,avca,cas,amnf,auto,arsd,abhh,btj
abkd,ady,atro,aly,bbc,atea,wtr,arp,acas,aee,uhal,dbrn,boom,ddd
rail,gwr,gdi,fmcn,gol,efh,ers,ffex,fmcn,ge,gil,komg,ovti,baby
nvtl,netl,novl,ora,rdcm,silc,qlty,tie,tgis,wdc,wpcs,xrtx,zons
VRDM at 0.05 and a price target of 0.75 is that is 1500%.
VRDM added by Stockster after the bell... WE'll watch it.
Close of day trading results for the lists:
Long Term Earnings Stocks: 72% up and 28% down
MDG New Rallies: 63% up and 37% down
MDG List 38% up or even 62% down: Loss of 8.8%
Nasdaq 100 63% up and 37% down
New Prospects 57% up or even 43% down
OTC - Advisors 60% up and 40% down
OTC Picks - 84% up and 16% down (from midday ).
OTCBB - 60% up or even and 40% down.
Long Term Winners list - 50% up and 50% down
MDG Multi Day Gainers LIST Week of March 17, 2006
Daily Charts of the top performers on the markets. Daily charts chosen with a 25 period SMA line to be a buy/sell trigger. 15 and 1 minute charts are too sensitive to indicate good sell points.
In daily chart measurements in many charts the 50 day is too loose and the 10 day is too tight so the 25 day strikes a good compromise to draw an SMA trendline in a realistic buy/sell trigger point that prevents large percentage downturns.
Chart watching standard. On the Daily charts the 50 period sma is too loose for catching drops. SOOOOO, the 10 period sma on the Daily charts is "looking" more appropriate as a buy/sell trigger.
PTSC daily charts could be at a head and shoulders top will watch closely in the next 2 trading days.
SPHM on watch for adjustment on the daily charts for start of a downtrend or a market top, will watch for a day or 2 more to see.
LVCP produces a great one day chart at 41% gain so far. Daytraders dream today.
Added http://www.earningsview.com to the billboard to indicate a future need to integrate NYSE, AMEX, and Nasdaq stable earnings with high performance PPS stocks in the Multidaygainers (MDG ) list.
MDG new prospects and new rallies outperforming the MDG list as of this mornings midday results.
MDG new prospects and new rallies outperforming the MDG list as of this mornings midday results.
OTC Picks combined midday and premarket lead to a 75% up and 25% down result. midday.
76 posts today, alot of stuff to cover...
SPHM (TRMB) shows financial 10 K's for March 2006 as the only one of 8 stocks in the MDG list with solid financials that will grow to change as performance is MEASURED with solid and less risky or more long term plays with solid financials from the NYSE, AMEX, and Nasdaq.... Will take time though.
MDG list Earnings View to look for solid financials....
NONE of the MDG list stocks have financials reported on WWW.earningsview.com later than 04. SOoooooo this can be worked on to find stocks with more solid financials for this list in the future.
SPHM on watch... Down 20% the daily chart shows that it is only a small percentage of its rise so will hold.
AVNT up 30% from the Top 100 OTCBB lists.
REUTERS Watson Pharmaceuticals to buy Andrx for $1.9 bln
CHICAGO, March 13 (Reuters) - Watson Pharmaceuticals Inc.
<WPI.N> has signed a definitive agreement to buy fellow generic
drug maker Andrx Corp. <ADRX.O> for $1.9 billion, the companies
said on Monday.
Watson will acquire all outstanding common stock of Andrx
for $25 per share, they said.
( Symbols:
de;ADX de;WAP de;WAPF de;WAPX gb;ADX us;ADRX us;WPI
Source RTRS Reuters News
REUTERS Capital One to buy North Fork for $14.6 billion
(Adds background throughout)
By Mark McSherry
NEW YORK, March 13 (Reuters) - Capital One Financial Corp.
<COF.N> said it would buy North Fork Bancorp Inc. <NFB.N> for
$14.6 billion, cutting its dependence on Visa and Mastercard
business and giving it a strong retail banking foothold in the
New York area.
A combined Capital One and North Fork would be the No. 3
New York-area bank by deposits after Citigroup Inc. <C.N> and
JPMorgan Chase & Co. <JPM.N>, and the 8th-largest U.S. bank by
assets.
North Fork shares jumped 16.5 percent, while Capital One
fell 6.3 percent in early trading.
Together with its $5 billion purchase of Hibernia Corp., a
Louisiana and Texas retail bank, in November, Capital One, the
No. 4 Visa and MasterCard credit card issuer, would further
reduces its dependence on credit cards.
North Fork, based in Melville, New York, operates 353
branches, and Hibernia operated about 300.
"With North Fork, Capital One will be more balanced and
more diversified," said Richard Fairbank, Capital One's chief
executive, on a conference call.
McLean, Virginia-based Capital One agreed late Sunday to
pay $31.18 per North Fork share, a 22.8 percent premium over
Friday's closing price. North Fork shareholders will receive
cash or stock for their shares, in either case equal to $11.25
in cash plus 0.2216 Capital One shares for each share.
The price is equal to about 16.1 times estimated 2006
profit for North Fork, and 1.6 times book value. North Fork
shares have fallen 15 percent from their 52-week high in July.
The transaction is expected to close in the fourth
quarter.
Capital One expects $275 million in pretax savings from the
transaction, and sees the deal adding slightly to profit
beginning in 2008.
North Fork shares rose $4.10, or 17.7 percent, to $29.90,
while Capital One fell $4.68, or 5.2 percent, to $85.24.
UNDER PRESSURE
The combined company will have more than $84 billion in
deposits, a $143 billion managed loan portfolio, more than 50
million customer accounts and 655 branches.
Capital One, known for its cheeky television advertising
featuring actor David Spade, has been one of the
fastest-growing financial services companies since it was spun
off from Signet Banking in 1994.
But Capital One has been under pressure to find new
businesses and cut costs as demand for credit cards slows
following years of explosive growth.
Analysts had thought Capital One might be acquired,
particularly after Bank of America Corp. <BAC.N> purchased card
issuer MBNA Corp., but Capital One's new banking clout and size
could diminish that attraction.
North Fork Chief Executive John Kanas will become president
of Capital One's banking business, reporting to Fairbank, and
will join Capital One's board of directors.
Herb Boydstun, president of Capital One's bank unit, will
report to Kanas and oversee banking in Louisiana and Texas.
Capital One still expects 2006 profit of $7.40 to $7.80 per
share, excluding North Fork. Analysts polled by Reuters
Estimates, on average, expected $7.70.
Capital One stock dropped $5.67 to $84.25, while North Fork
advanced $4.21 to $29.61.
JPMorgan, Citigroup and law firm Cleary Gottlieb Steen &
Hamilton LLP advised Capital One. Sandler O'Neill & Partners
LP, Keefe, Bruyette & Woods Inc. and law firm Wachtell, Lipton,
Rosen & Katz advised North Fork.
(Additional reporting by Michele Gershberg and Jonathan
Stempel)
(c) Reuters 2006. All rights reserved. Republication or redistribution of
Reuters content, including by caching, framing or similar means, is
expressly prohibited without the prior written consent of Reuters. Reuters
and the Reuters sphere logo are registered trademarks and trademarks of
the Reuters group of companies around the world.
13Mar06 14:51 GMT
Symbols:
de;CFX de;CFXF de;NCB de;NCBF de;NCBS de;NCBX de;TRV de;TRVF de;TRVS
de;TRVX gb;BAC gb;CGP gb;JPM jp;8634 mx;JPM us;BAC us;C us;COF us;JPM
us;NFB
Source RTRS Reuters News
Categories:
Amex:TTG Tutogen Medical, Inc. Contacted by Zimmer Holdings, Inc. to Discuss Potential Strategic...
ALACHUA, Fla., March 13 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc.
(Amex: TTG), a leading manufacturer of sterile biological implant products
made from human (allograft) and animal (xenograft) tissue, today announced
that Mr. Guy L. Mayer, Chief Executive Officer of Tutogen, has been contacted
by representatives of Zimmer Holdings, Inc. to enter into discussions on a
range of potential strategic transactions, which could possibly include
further investment by Zimmer in securities of Tutogen Medical or the
acquisition by Zimmer of some or all of the outstanding common stock of
Tutogen.
Zimmer Holdings, Inc. filed Schedule 13 D/A on Friday, March 10, 2006
expressing its intention to initiate discussions with Tutogen Medical, Inc.
Guy L. Mayer, president and CEO of Tutogen Medical, said, "We have made a
great deal of progress in the past year in positioning the Company for
improved performance. We believe this approach by Zimmer is indicative of
that progress. We look forward to considering any and all strategic options
that will help us to expand the reach of our products worldwide and that will
appropriately enhance value for our loyal shareholders."
About Tutogen Medical, Inc.
Tutogen Medical, Inc. manufactures sterile biological implant products
made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes
its Tutoplast Process(R) of tissue preservation and viral inactivation to
manufacture and deliver sterile bio-implants used in spinal/trauma, urology,
dental, ophthalmology, and general surgery procedures. The Company's
Tutoplast(R) products are sold and distributed worldwide by Zimmer Spine and
Zimmer Dental, subsidiaries of Zimmer Holdings, Inc. the Mentor Corporation,
IOP, Inc. and through independent distributors and subsidiaries in the U.S.
and other international markets. For more information, visit the Company's
Web site at http://www.tutogen.com .
Contacts:
Bob Johnston
Chief Financial Officer Lytham Partners, LLC
Tutogen Medical, Inc. Institutional: Joe Diaz
386-462-0402 ext. 109 Retail: Joe Dorame
bjohnston@tutogen.com 602-889-9700
SOURCE Tutogen Medical, Inc.
Bob Johnston, Chief Financial Officer of Tutogen Medical, Inc.,
+1-386-462-0402, ext. 109, bjohnston@tutogen.com; or Institutional, Joe Diaz,
or Retail, Joe Dorame, both of Lytham Partners, LLC, +1-602-889-9700, for
Tutogen Medical, Inc.
13Mar06 14:51 GMT
Symbols:
us;TTG
Source PRN PR Newswire
Categories:
NWI/BIO NWI/HEA NWI/MTC MST/I/BTC MST/I/DRG MST/I/HEA MST/I/MDV MST/L/EN
MST/R/US/FL TGT/PRX
Amex:TTG Tutogen Medical, Inc. Contacted by Zimmer Holdings, Inc. to Discuss Potential Strategic...
ALACHUA, Fla., March 13 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc.
(Amex: TTG), a leading manufacturer of sterile biological implant products
made from human (allograft) and animal (xenograft) tissue, today announced
that Mr. Guy L. Mayer, Chief Executive Officer of Tutogen, has been contacted
by representatives of Zimmer Holdings, Inc. to enter into discussions on a
range of potential strategic transactions, which could possibly include
further investment by Zimmer in securities of Tutogen Medical or the
acquisition by Zimmer of some or all of the outstanding common stock of
Tutogen.
Zimmer Holdings, Inc. filed Schedule 13 D/A on Friday, March 10, 2006
expressing its intention to initiate discussions with Tutogen Medical, Inc.
Guy L. Mayer, president and CEO of Tutogen Medical, said, "We have made a
great deal of progress in the past year in positioning the Company for
improved performance. We believe this approach by Zimmer is indicative of
that progress. We look forward to considering any and all strategic options
that will help us to expand the reach of our products worldwide and that will
appropriately enhance value for our loyal shareholders."
About Tutogen Medical, Inc.
Tutogen Medical, Inc. manufactures sterile biological implant products
made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes
its Tutoplast Process(R) of tissue preservation and viral inactivation to
manufacture and deliver sterile bio-implants used in spinal/trauma, urology,
dental, ophthalmology, and general surgery procedures. The Company's
Tutoplast(R) products are sold and distributed worldwide by Zimmer Spine and
Zimmer Dental, subsidiaries of Zimmer Holdings, Inc. the Mentor Corporation,
IOP, Inc. and through independent distributors and subsidiaries in the U.S.
and other international markets. For more information, visit the Company's
Web site at http://www.tutogen.com .
Contacts:
Bob Johnston
Chief Financial Officer Lytham Partners, LLC
Tutogen Medical, Inc. Institutional: Joe Diaz
386-462-0402 ext. 109 Retail: Joe Dorame
bjohnston@tutogen.com 602-889-9700
SOURCE Tutogen Medical, Inc.
Bob Johnston, Chief Financial Officer of Tutogen Medical, Inc.,
+1-386-462-0402, ext. 109, bjohnston@tutogen.com; or Institutional, Joe Diaz,
or Retail, Joe Dorame, both of Lytham Partners, LLC, +1-602-889-9700, for
Tutogen Medical, Inc.
13Mar06 14:51 GMT
Symbols:
us;TTG
Source PRN PR Newswire
Categories:
NWI/BIO NWI/HEA NWI/MTC MST/I/BTC MST/I/DRG MST/I/HEA MST/I/MDV MST/L/EN
MST/R/US/FL TGT/PRX
REUTERS UPDATE 1-Casino firm Pinnacle to buy Aztar for $1.45 bln [FWYJRCM]
(Adds details, background)
NEW YORK, March 13 (Reuters) - Casino operator Pinnacle
Entertainment Inc. <PNK.N> on Monday said it would buy Aztar
Corp. <AZR.N> for about $1.45 billion in cash, extending its
reach into U.S. gambling markets such as Las Vegas and Atlantic
City.
Pinnacle said it would buy all of the outstanding shares of
Aztar for $38 each in cash.
The company said the deal, which also involves the
assumption of about $723 million in Aztar debt, represents a
premium of about 24 percent over Aztar's closing price on March
10.
Aztar shares were up $7.30, or 24 percent, at $38.00 in
morning trading on the New York Stock Exchange. Pinnacle was up
33 cents, or 1.2 percent, at $28.29.
The combined company will have 12 gaming properties in the
United States, including Nevada, New Jersey, Louisiana,
Missouri and Indiana, and more than 8,800 hotel rooms.
Phoenix-based Aztar owns the Tropicana casino resorts in
Las Vegas and Atlantic city, among others, while Las
Vegas-based Pinnacle owns such properties as the L'Auberge du
Lac Hotel and Casino in Lake Charles, Louisiana.
The deal gives Pinnacle cross-marketing opportunities,
which could help it attract more customers to its casinos.
"We intend to create a nationwide casino network, not unlike
that of some of our larger competitors," Pinnacle Chief
Executive Daniel Lee said in a statement. "We believe that we
will be able to leverage the combined company's extensive
network to increase customer loyalty across the system."
The boards of directors of both companies have approved the
deal, which will be fully financed and is expected to close by
the end of the year, Pinnacle said.
Pinnacle said it had received a financing commitment from
Bear, Stearns & Co. Inc. and Lehman Brothers Inc. to complete
the transaction.
( Symbols:
de;ZTG de;ZTGF de;ZTGX us;AZR us;PNK
Source RTRS Reuters News
Nasdaq/NYSE/AMEX stocks that are newsworthy....
FNSR in the last quarter at 500% increase, wow.
ADRX up on big dollar volume
CTIB has had 600% climbs recently ( huge gaps )
From the NYSE:
rev.rt up 100%
azr up 30%
nfb up 10%
From the AMEX:
SVI.WS up 46%
TTG up 21%
NI up 20%
OTCBB website only showing results as of Friday ? Well thats a little slow.
DGKO an interesting intraday chart from Pink Sheets.
RSHN tradable with alot of volume today.
FDEG from the PinkSheets showing tradable action today with a decent 3 month chart.
DCNAQ an interesting one from the Pinksheets.
FTGX chart not so bad up 12% this morning. ( seems to still be rising anyways. ).
Time to review the Pinksheets, OTCBB websites, and the top ten lists for the settled in perfromers of today.
60 posts thusfar today, boy an active morning.
MDG LIST settles in at an average of 21% up.
NOTE: These percentages are in reference to close of trade yesterday, and not the MDG list purchasse time and price of this morning. ( actual values not as high but post indicates that despite what is now a 50/50 morning the stocks are averaging higher ).
HOT HOT HOT LIST from the NEW Prospects LIST.
DVINQ up 53%
ONEV up 33%
LVCP up 30%
RTGV up 30%
XSNX up 11%
SUWN up 10%
GWGO up 8.5%
GTEC up 7%
Thusfar anyways.
ONEV added to the MDG New Prospects List.
UPDATED MDG LIST Final as of Monday March 13 open of trade.
DVINQ
LFWK
GTEC
MICG
MEDC
PTSC
CRGO
SPHM
The list is currently 50% up and 50% down so it may be a frothy week. Oh well impossible to predict frothiness sometimes.
MDG LIST UPDATE DVINQ purchassed at .055. ( a little scary for the gap but makes sense on the daily charts. )
MEDC, SPHM, and now CRGO does a reversal... Oh boy, new it couldnt be that easy.
PTSC plunging, down 9% but will hold and wait on that.
MEDC up from a negative to a positive 5%
CRGO still up and turned the corner so it looks like a safe purchasse for the MDG list. up 7% from previous close.
DVINQ still not understood and too high a gap to purchasse on so we will wait on that one.